Acquisitions29 Jan 2026, 02:01 am
Piramal Pharma Ltd Subsidiary to Acquire Kenalog® from Bristol-Myers Squibb for Up to US$ 100 Million
AI Summary
Piramal Critical Care B.V., a step-down wholly owned subsidiary of Piramal Pharma Limited, has entered into a definitive agreement with Bristol-Myers Squibb Company (BMS) for the acquisition of Kenalog® and its associated brands for an upfront consideration of US$ 35 million and a contingent consideration of up to US$ 65 million. The transaction, which does not involve related parties and is expected to leverage the company's extensive distribution network and broaden its product portfolio, is subject to the fulfillment of certain closing conditions.
Key Highlights
- Piramal Critical Care B.V. to acquire Kenalog® and its associated brands from Bristol-Myers Squibb Company for up to US$ 100 million
- Transaction includes an upfront consideration of US$ 35 million and a contingent consideration of up to US$ 65 million
- Kenalog® is a branded commercial injectable product containing Triamcinolone Acetonide, used as an adjunctive therapy in various inflammatory conditions
- Transaction expected to leverage the company's extensive distribution network and broaden its product portfolio
- Transaction does not involve related parties and is subject to the fulfillment of certain closing conditions